NCT03936218View on ClinicalTrials.gov

Goserelin 10.8mg Injection in Treatment of Advanced Prostate Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

94

Participants

Timeline

Start Date

September 30, 2020

Primary Completion Date

November 30, 2023

Study Completion Date

April 1, 2024

Conditions
Advanced Prostate Cancer
Interventions
DRUG

Inj. Goserelin (Test) Subcutaneously

10.8 mg, subcutaneously at every 3 month

DRUG

Inj. Zoladex (Reference) Subcutaneously

10.8 mg, Subcutaneously at every 3 month

Trial Locations (1)

530017

Mahatma Gandhi Cancer Hospital & Research Institute, Visakhapatnam

Sponsors
All Listed Sponsors
lead

Eurofarma Laboratorios S.A.

INDUSTRY